Invivo Therapeutics (NVIV) Enrolls New Patient into INSPIRE Study
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) announced that a new patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at Oregon Health & Science University (OHSU) in Portland, Oregon. Ahmed M. Raslan, M.D. and Jason J Chang, M.D., Assistant Professors of Neurological Surgery and study investigators, performed surgery and the implantation on the T9 neurologically complete patient approximately 36 hours after the injury occurred.
Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “We are pleased that the patient is doing well and wish them continued recovery. We have nine patients enrolled and in follow up and, because we now have over 25 INSPIRE sites open, expect enrollment to increase in the coming months.”
For more information, please visit the company’s ClinicalTrials.gov registration site: http://clinicaltrials.gov/ct2/show/study/NCT02138110
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ChemoCentryx (CCXI) Announces Presentation of Data from Ongoing Phase Ib Trial of CCR2 Inhibitor CCX872 at ASCO
- Amaya (AYA) Sees Higher 2016 Revs, EBITDA, EPS; CFO Daniel Sebag to Retire
- Seagate Technology (STX) Appoints Mark Adams to Board of Directors
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!